Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Vasc Med. 2019 Jul 27;24(5):442–451. doi: 10.1177/1358863X19862043

Table 2.

Effect of PCDT on Venous Sonographic Outcomes at 1 month and 12 months

Overall Trial Status at 1 Month PCDT1 Control p-value2
CFV diameter (mm), mean (SD) 1.5 (4.3) 3.4 (7.3) 0.0002
PV diameter (mm), mean (SD) 4.1 (4.9) 6.4 (7.2) <0.0001
Ultrasound Substudy Status at 12 Months PCDT1 Control p-value2
CFV diameter (mm), mean (SD) 1.2 (3.4) 3.2 (4.7) 0.003
PV diameter (mm), mean (SD) 3.9 (4.1) 7.2 (5.1) 0.004
Obstruction score3, mean (SD) 0.08 (0.4) 0.14 (0.4) 0.49
Reflux score3, mean (SD) 2.7 (1.7) 3.0 (1.7) 0.39
Any reflux present, n (%) 51/60 (85%) 57/63 (91%) 0.35
Deep reflux present, n (%) 50/60 (83%) 54/63 (86%) 0.71
Superficial reflux present, n (%) 26/60 (43%) 23/63 (37%) 0.44
1

Treatment groups are per-protocol patients

2

Comparisons adjusted for baseline compressibility status for CFV, PV and FV at 1 month and 1 year

3

Scores are derived from the modified Venous Segmental Disease Scale (VSDS)

CFV=Common Femoral Vein,, PCDT=Pharmacomechanical Catheter-Directed Thrombolysis, PV=Popliteal Vein, SD=Standard Deviation